Pathway analysis provides insight into the genetic susceptibility to hepatocellular carcinoma and insight into immuno-therapy treatment response

Abstract

Clear evidence exists for genetic susceptibility to hepatocellular carcinoma (HCC). Genome-wide association studies have identified multiple candidate susceptibility loci. These loci suggest that genetic variation in the immune system may underpin HCC susceptibility. Genes for the antigen processing and presentation pathway have been observed to be significantly enriched across studies and the pathway is identified directly through genome-wide studies of variation using pathway methods. Detailed analysis of the pathway indicates both variation in the antigen presenting loci and in the antigen processing are different in cases in controls. Pathway analysis at the transcriptional level also shows difference between normal liver and liver in individuals with HCC. Assessing differences in the pathway may prove important in improving immune therapy for HCC and in identifying responders for immune checkpoint therapy.

Keywords

Hepatocellular carcinoma / genetic susceptibility / genome-wide association study / pathway analysis / antigen presentation and processing / immune checkpoint therapy

References

[1] Torre LA,Ward EM.Global cancer incidence and mortality rates and trends - an update.Cancer Epidemiol Prev Biomark2016;25:16-27

[2] Petrick JL,Laversanne M,Bray F.International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.Int J Cancer2016;139:1534-45 PMCID:PMC5310166

[3] McGlynn KA,London WT.Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.Clin Liver Dis2015;19:223-38 PMCID:PMC4712629

[4] Makarova-Rusher OV,McNeel TS,Duffy AG,Greten TF.Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.Cancer2016;122:1757-65 PMCID:PMC5548177

[5] Jemal A,Johnson CJ,Ma J,Mariotto A,Wilson R,Anderson RN,Kohler BA,Feuer EJ.Annual report to the nation on the status of cancer, 1975-2014, featuring survival.J Natl Cancer Inst2017;109:djx030 PMCID:PMC5409140

[6] Fujimoto A,Totoki Y,Kato M,Tanaka H,Kawakami Y,Gotoh K,Wardell CP,Nakamura T,Arihiro K,Abe T,Maejima K,Ohsawa A,Nakamura H,Hosoda F,Ohashi S,Nagae G,Ueda H,Ojima H,Okusaka T,Marubashi S,Hirano S,Ohdan H,Ishikawa O,Chayama K,Aburatani H,Nakagawa H.Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer.Nat Genet2016;48:500-9

[7] Schulze K,Letouzé E,Calderaro J,Couchy G,Shinde J,Calatayud AL,Pelletier L,Laurent A,Mazzaferro V,Villanueva A,Bioulac-Sage P,Llovet JM.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.Nat Genet2015;47:505-11 PMCID:PMC4587544

[8] Cancer Genome Atlas Research Network.Comprehensive and integrative genomic characterization of hepatocellular carcinoma.Cell2017;169:1327-41.e23 PMCID:PMC5680778

[9] Shen FM,Gong HM,King MC.Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: interaction of inherited susceptibility and hepatitis B viral infection.Am J Hum Genet1991;49:88-93 PMCID:PMC1683220

[10] Yu MW,Liaw YF,Lee SD,Chen PJ,Lee PH.Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives.J Natl Cancer Inst2000;92:1159-64

[11] Hassan MM,Thomas MB,Patt YZ,Glover KY,Lozano RD,Nguyen NT,Chan W,Li D.The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States.J Hepatol2009;50:334-41 PMCID:PMC2658718

[12] Dragani TA.Risk of HCC: genetic heterogeneity and complex genetics.J Hepatol2010;52:252-7

[13] Turati F,Talamini R,Malvezzi M,Franceschi S,Polesel J,La Vecchia C,Decarli A.Family history of liver cancer and hepatocellular carcinoma.Hepatology2012;55:1416-25

[14] Caruso S,Letouzé E,Couchy G,Luciani A,Bioulac-Sage P,Imbeaud S.Germline and somatic DICER1 mutations in familial and sporadic liver tumors.J Hepatol2017;66:734-42

[15] Jin F,Jing JC,Qu LS.Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review.J Cancer Res Clin Oncol2011;137:1095-104

[16] MacArthur J,Cerezo M,Hall P,Junkins H,Milano A,Pendlington ZM,Burdett T,Flicek P,Parkinson H.The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog).Nucleic Acids Res2017;45:D896-901 PMCID:PMC5210590

[17] Braun R.Pathways of distinction analysis: a new technique for multi-SNP analysis of GWAS data.PLoS Genet2011;7:e1002101 PMCID:PMC3111473

[18] Purcell S,Todd-Brown K,Ferreira MA,Maller J,de Bakker PI,Sham PC.PLINK: a tool set for whole-genome association and population-based linkage analyses.Am J Hum Genet2007;81:559-75 PMCID:PMC1950838

[19] GTEx Consortium.Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans..Science2015;348:648-60 PMCID:PMC4547484

[20] GTEx Consortium; Laboratory, Data Analysis &Coordinating Center (LDACC)-Analysis Working Group; Statistical Methods groups-Analysis Working Group; Enhancing GTEx (eGTEx) groups; NIH Common Fund; NIH/NCI; NIH/NHGRI; NIH/NIMH; NIH/NIDA; Biospecimen Collection Source Site-NDRI; Biospecimen Collection Source Site-RPCI; Biospecimen Core Resource-VARI; Brain Bank Repository-University of Miami Brain Endowment Bank; Leidos Biomedical-Project Management; ELSI Study; Genome Browser Data Integration & Visualization-EBI; Genome Browser Data Integration & Visualization-UCSC Genomics Institute, University of California Santa Cruz; Lead analysts; Laboratory, Data Analysis & Coordinating Center (LDACC); NIH program management; Biospecimen collection; Pathology; eQTL manuscript working group; Battle A, Brown CD, Engelhardt BE, Montgomery SB. Genetic effects on gene expression across human tissues. Nature 2017;550;204-13. PMCID:PMC5776756

[21] Saha A,Gewirtz ADH,Gao C,GTEx Consortium GTE,Battle A.Co-expression networks reveal the tissue-specific regulation of transcription and splicing.Genome Res2017;27:1843-58 PMCID:PMC5668942

[22] Kim D,Salzberg SL.HISAT: a fast spliced aligner with low memory requirements.Nat Methods2015;12:357-60 PMCID:PMC4655817

[23] Pertea M,Pertea GM,Salzberg SL.Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown.Nat Protoc2016;11:1650-67 PMCID:PMC5032908

[24] Liao Y,Shi W.featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.Bioinformatics2014;30:923-30

[25] Law CW,Shi W.voom: precision weights unlock linear model analysis tools for RNA-seq read counts.Genome Biol2014;15:R29 PMCID:PMC4053721

[26] Ritchie ME,Wu D,Law CW,Smyth GK.limma powers differential expression analyses for RNA-sequencing and microarray studies.Nucleic Acids Res2015;43:e47 PMCID:PMC4402510

[27] Efroni S,Buetow KH.Identification of key processes underlying cancer phenotypes using biologic pathway analysis.PLoS One2007;2:e425 PMCID:PMC1855990

[28] Efroni S,Schaefer CG.Superposition of transcriptional behaviors determines gene state.PLoS One2008;3:e2901 PMCID:PMC2488367

[29] Greenblum SI,Schaefer CF.The PathOlogist: an automated tool for pathway-centric analysis.BMC Bioinformatics2011;12:133 PMCID:PMC3098789

[30] Sharma P.The future of immune checkpoint therapy.Science2015;348:56-61

[31] Garbe C,Hauschild A,Middleton M,Grob JJ,Newton-Bishop J,Pehamberger H,European Dermatology Forum (EDF) EDF,European Organisation for Research and Treatment of Cancer (EORTC) EORT.Diagnosis and treatment of melanoma.European consensus-based interdisciplinary guideline - update2016;63:201-17

[32] Garon EB,Hui R,Balmanoukian AS,Patnaik A,Gubens M,Carcereny E,Felip E,Hellmann MD,Goldman JW,Dolled-Filhart M,Zhang J,Rangwala R,Roach C,Gandhi L.Pembrolizumab for the treatment of non-small-cell lung cancer.N Engl J Med2015;372:2018-28

[33] Sharma P,Wargo JA.Primary, adaptive, and acquired resistance to cancer immunotherapy.Cell2017;168:707-23 PMCID:PMC5391692

[34] Le DT,Smith KN,Bartlett BR,Lu S,Wilt C,Wong F,Rucki AA,Donehower R,Fisher GA,Lee JJ,Duffy AG,Eyring AD,Joe A,Holdhoff M,Cope L,Zhou S,Armstrong DK,Fader AN,Housseau F,Xiao N,Papadopoulos N,Eshleman JR,Anders RA.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science2017;357:409-13 PMCID:PMC5576142

[35] Goodman AM,Bazhenova L,Frampton GM,Stephens PJ,Kurzrock R.Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers.Mol Cancer Ther2017;16:2598-608